Century Therapeutics, Inc. (NASDAQ:IPSC) Receives $10.00 Consensus PT from Analysts

Century Therapeutics, Inc. (NASDAQ:IPSC) has been assigned a consensus rating of “Buy” from the six brokerages that are covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $10.00.

A number of equities research analysts recently commented on IPSC shares. Piper Sandler dropped their price objective on Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating for the company in a report on Monday, December 30th. Chardan Capital reduced their price target on shares of Century Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of Century Therapeutics in a research report on Wednesday, January 22nd. Finally, Guggenheim reiterated a “buy” rating on shares of Century Therapeutics in a report on Wednesday, January 22nd.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC lifted its holdings in Century Therapeutics by 3.5% during the 3rd quarter. Geode Capital Management LLC now owns 968,182 shares of the company’s stock valued at $1,656,000 after purchasing an additional 32,614 shares during the last quarter. Barclays PLC lifted its stake in shares of Century Therapeutics by 283.6% during the 3rd quarter. Barclays PLC now owns 61,945 shares of the company’s stock worth $106,000 after buying an additional 45,797 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Century Therapeutics by 257.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 71,721 shares of the company’s stock worth $123,000 after buying an additional 51,664 shares during the period. State Street Corp lifted its position in Century Therapeutics by 7.4% during the third quarter. State Street Corp now owns 836,914 shares of the company’s stock worth $1,431,000 after acquiring an additional 57,323 shares during the last quarter. Finally, Wellington Management Group LLP bought a new stake in shares of Century Therapeutics during the third quarter worth approximately $284,000. 50.20% of the stock is owned by institutional investors and hedge funds.

Century Therapeutics Trading Down 2.5 %

NASDAQ IPSC opened at $0.73 on Friday. The stock has a 50-day simple moving average of $0.92 and a 200 day simple moving average of $1.31. The company has a market capitalization of $62.07 million, a PE ratio of -0.39 and a beta of 1.73. Century Therapeutics has a 12 month low of $0.68 and a 12 month high of $5.51.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.